Introduction: From Experimental to Essential Not long ago, cell and gene therapy sounded like science fiction. Editing DNA Reprogramming cells Treating diseases at their genetic root But in 2026, that

Introduction: Innovation Is Global, Regulation Is Not In 2026, biotech innovation is accelerating faster than ever. But regulation? It’s moving at a different speed. As companies race to develop gene

Introduction: The Moment Drug Discovery Stopped Being Human-Only For decades, drug discovery followed a familiar path, slow, expensive, and uncertain. A single drug could take over 10 years and billions

Introduction: A Dynamic Funding Environment Biotech fundraising in 2026 is far from uniform, but it’s gaining clarity. After years of wide swings in capital availability, investor focus is sharpening on

Introduction: Why JPM Week Still Sets the Biotech Agenda Every January, JPM Week in San Francisco does more than convene executives and investors—it quietly sets the direction for biotech innovation

Introduction: A More Disciplined Era for Biotech Startups The biotech sector is entering 2026 with a markedly different funding mood than the exuberant years of the early 2020s. Easy money,

The global regulatory landscape for biotechnology is in the midst of a major evolution driven by scientific advances, geopolitical concerns, sustainability priorities, and shifting public expectations. For biotech startups, this

2025 has been a landmark year for gene editing not because of hype, but because of real patients walking out of clinics, researchers refining the tools, and regulators beginning to

In a small lab in Zagreb, researchers quietly mapped 90 new genes tied to immunoglobulin, G (IgG) glycosylation. The finding may seem arcane, but for drug makers simply trying to

When algorithms become the lab’s new pipette, biology is rewriting its own rulebook. The New Alchemy Picture a lab where silico meets vivo, software whispers into petri dishes, and bits